Phreesia Inc (PHR)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NYSE
Market Cap: $787.68M
Last updated: Nov 17, 2026 at 11:05 AM ET
Phreesia Inc (PHR) P/E Ratio & Valuation History
Phreesia (PHR) trades at 13.2x trailing earnings and 1.6x sales. Its P/S of 1.6x is below its 5-year median of 3.6x. Its forward P/E is 14.3x. The median P/E across 6 similar companies is 36.0x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 7.7% lower over the next year. Its free cash flow yield is 8.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 13.2x |
| Forward P/E | 14.3x |
| Price to sales | 1.6x |
| Price to book | 2.1x |
| Price to FCF | 11.8x |
| PEG | N/A |
| FCF yield | 8.5% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.6x | 3.6x | N/A |
| P/B | 2.1x | 4.6x | N/A |
Valuation History
Over the 7 year ends shown, its P/S ranged from 2.2x in 2025 to 14.5x in 2020. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $16.92 | 24.3x | 2.2x | 3.2x |
| 2024 | $25.16 | N/A | 3.5x | 5.7x |
| 2023 | $23.15 | N/A | 3.7x | 4.8x |
| 2022 | $32.36 | N/A | 6.4x | 5.3x |
| 2021 | $41.66 | N/A | 10.1x | 4.6x |
| 2020 | $54.26 | N/A | 14.5x | 7.7x |
| 2019 | $26.64 | N/A | 3.7x | 9.3x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PHR
What is PHR's forward P/E ratio?
Phreesia has a forward P/E ratio of 14.3x.
Is PHR stock overvalued?
GNG's valuation label for PHR is Undervalued. Its P/E of 13.2x compares with a median of 36.0x across 6 similar companies.
What is PHR's price to sales ratio?
Phreesia has a price to sales ratio of 1.6x.
PHR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors